# Research Idea Ranking

**Generated:** 2026-01-29T17:34:55.829679
**Model:** gpt-5.2 (reasoning: high)
**Tokens:** 5951
**OpenAI Response ID:** resp_058b5aed4b98771400697b8bd5a6108194a8e8e159ee318c95

---

### Rankings

**#1: Must-Access PDMP Mandates and Prime-Age Labor Force Participation**
- **Score: 67/100**
- **Strengths:** Good policy variation (≈40 states, staggered 2012–2022) and strong sample size; using Callaway–Sant’Anna is a clear improvement over older TWFE work and allows cohort/event-time diagnostics. The question is policy-relevant given opioids’ plausible labor-supply and disability pathways.
- **Concerns:** Treatment adoption is likely endogenous to worsening opioid conditions (and correlated policy bundles), so causal interpretation hinges on convincing pre-trends and robustness to concurrent opioid/health policies. Labor-market outcomes in CPS may be “diluted” because only a subset of prime-age adults is directly affected by prescribing constraints.
- **Novelty Assessment:** **Moderate.** There is a large PDMP literature (mostly on prescribing/overdoses); fewer papers link *must-access* mandates specifically to labor outcomes with modern staggered-DiD methods and a post-2020 window. Incremental but still publishable if executed carefully.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (CPS ASEC 2007–2023 gives ≥5 pre-years for most adopting cohorts)
  - **Selection into treatment:** **Marginal** (must-access mandates plausibly respond to opioid misuse/overdose trends; show strong event-study pre-trends on *labor outcomes* and ideally on opioid-severity proxies)
  - **Comparison group:** **Marginal** (never-/later-treated states may differ systematically in opioid exposure, rurality, industry mix)
  - **Treatment clusters:** **Strong** (≈40 state adoptions)
  - **Concurrent policies:** **Marginal** (naloxone access laws, pill-mill laws, Medicaid expansion, pain-clinic regs, marijuana legalization, etc. can coincide; you’ll need a credible policy-controls/stacked designs sensitivity set)
  - **Outcome-Policy Alignment:** **Marginal** (PDMP affects prescribing → misuse/health → employment/disability; plausible but indirect, so nulls are harder to interpret)
  - **Data-Outcome Timing:** **Marginal** (CPS **ASEC is fielded Feb–Apr**; labor-force status is “current” around March, while some ASEC items (income/program receipt) reference the **prior calendar year**. Must-access effective dates are often mid-year, creating partial exposure unless treatment is aligned carefully—e.g., define “treated year” only when mandate effective by Jan 1, or move to monthly CPS for LFP.)
  - **Outcome Dilution:** **Marginal** (policy most directly affects people seeking controlled substances; that’s not the full 25–54 sample. If annual controlled-substance use is, say, ~20–30% but labor effects concentrate among a smaller high-risk subset, intent-to-treat effects on overall LFP may be small. Mitigate with high-risk subgroups: low-edu men, high-injury occupations, high-opioid states, prior disability-limitation reporters, etc.)
- **Recommendation:** **PURSUE (conditional on: (i) clear timing alignment—prefer monthly CPS for LFP or strict “full-exposure year” coding; (ii) strong pre-trends/event-study diagnostics; (iii) serious sensitivity to concurrent opioid policies; (iv) subgroup/targeted outcomes to address dilution and power).**

---

**#2: State Drug Price Transparency Laws and Out-of-Pocket Prescription Spending**
- **Score: 54/100**
- **Strengths:** Outcome-policy alignment is direct and highly policy-relevant; transparency laws are less studied than other pharma policies, and a credible null would still matter. If you can get high-quality spending/utilization data, this could inform whether these laws materially affect consumers.
- **Concerns:** Data feasibility is the central risk: **MEPS has good Rx spending but state identifiers are typically restricted**, and CPS is generally too coarse/noisy for Rx out-of-pocket spending. Identification is also fragile because adoption may correlate with pre-existing high or rising drug costs and other contemporaneous state health-policy reforms (PBM regulation, Medicaid changes).
- **Novelty Assessment:** **Moderate.** There are fewer causal papers than for PDMPs, but the space is not empty—there are policy reports and some empirical work/working papers. Novelty depends heavily on assembling a clean, harmonized “effective” transparency-law dataset (many laws have limited enforcement/coverage).
- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (if you can use 2010–2015+ as pre for 2016+ adopters; many cohorts will have ≥5 pre-years)
  - **Selection into treatment:** **Marginal** (likely correlated with high drug spending growth and political ideology; must show pre-trends on OOP Rx spending and consider designs that lessen endogeneity, e.g., bordering-state comparisons, matching, or focusing on plausibly exogenous implementation shocks)
  - **Comparison group:** **Marginal** (adopters vs non-adopters may differ systematically—blue states, higher baseline prices, different insurance markets)
  - **Treatment clusters:** **Strong/Marginal** (≈20–25 states is okay but not huge; inference needs care)
  - **Concurrent policies:** **Marginal** (PBM laws, Medicaid preferred drug list changes, ACA/Medicaid expansion interactions, state reinsurance waivers—these can confound spending trends)
  - **Outcome-Policy Alignment:** **Strong** (OOP Rx spending/utilization is exactly the intended target)
  - **Data-Outcome Timing:** **Marginal** (annual spending measures can be partially exposed if laws take effect mid-year; you need “full-year exposed” coding or month-level spending data)
  - **Outcome Dilution:** **Strong/Marginal** (a large share of adults fill prescriptions, so not tiny; but many transparency laws only cover large price hikes or certain drugs—effects on *total* OOP may still be modest)
- **Recommendation:** **CONSIDER (conditional on: obtaining restricted-state MEPS or alternative claims/APCD data with state and month; building a credible “binding/enforced law” measure; and demonstrating clean pre-trends + robustness to concurrent state health-policy changes).**

---

**#3: State Adoption of Crisis Intervention Team (CIT) Training Mandates → Mental Health Arrest Diversion**
- **Score: 36/100**
- **Strengths:** Conceptually important and relatively under-studied at the state-policy level; if measured well, could speak directly to public safety and behavioral health system design.
- **Concerns:** The proposal currently has a major **measurement/outcome mismatch**: UCR/NIBRS typically does not cleanly capture “mental health-related offenses,” use-of-force (nationally comparable), or emergency detentions in a way that aligns with CIT mandates. CIT “mandates” are also heterogeneous (who must be trained, hours, funding, enforcement), and adoption likely follows high-profile incidents and policing trends—making DiD credibility difficult.
- **Novelty Assessment:** **High** on the *specific statewide mandate DiD*, but novelty cannot compensate for weak outcome measurement and likely heterogeneous/non-binding treatment.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Marginal** (could be strong in principle, but depends on when mandates start and whether consistent data exist pre-period)
  - **Selection into treatment:** **Weak** (very plausibly adopted in response to crises/trends in policing incidents or mental-health system failures)
  - **Comparison group:** **Marginal/Weak** (states adopting mandates may differ systematically in policing institutions and reporting; and NIBRS participation varies)
  - **Treatment clusters:** **Weak (unclear)** (you do not yet know how many states have *binding* mandates; if <10, inference is fragile)
  - **Concurrent policies:** **Weak** (police reforms, body cams, de-escalation training mandates, Medicaid behavioral-health expansions often move together)
  - **Outcome-Policy Alignment:** **Weak** (UCR/NIBRS does not cleanly measure “mental-health arrest diversion” or use-of-force in a consistent way; the key outcome is not well-captured)
  - **Data-Outcome Timing:** **Marginal** (even if adoption dates are known, training rollout/coverage lags create unclear exposure timing)
  - **Outcome Dilution:** **Weak** (CIT targets a small subset of encounters; broad arrest-rate outcomes are likely heavily diluted unless you have a precise mental-health-encounter measure)
- **Recommendation:** **SKIP (unless you can secure a dataset with directly aligned outcomes—e.g., 911 CAD data, EMS/ED crisis pickups, state involuntary commitment records, or agency-level CIT training coverage—plus a clearly binding mandate definition).**

---

### Summary

This batch has one clearly actionable project (**PDMP must-access → labor outcomes**) that is feasible and policy-relevant but needs careful work on **timing alignment, concurrent opioid policies, and dilution**. The drug transparency idea is potentially valuable but is **data-constrained** unless you can access restricted-state MEPS or claims/APCD data and harmonize what counts as a binding law. The CIT idea is the least promising as stated because **the proposed national crime datasets do not measure the mechanism-relevant outcomes**, and treatment definition/enforcement is likely too heterogeneous for credible DiD.